The Phase 2 Covid-19 trial of Rabeximod that has been conducted in Eastern Europe during Q1-Q2 2021 will be closed as the trial has been shown to have a sufficient number of patients enrolled to allow for statistical analysis.
Recently Cyxone reported that patient recruitment for the clinical study conducted in Covid-19 patients in Eastern Europe was challenged as Covid-19 cases declined and a study delay was predicted. Approximately 90 patients have been enrolled into the trial to date, and after reanalysis of the statistical requirements for study size it has been concluded that the trial currently has sufficient patients to power an analysis of the effect of Rabeximod over placebo, states the company in a press release.
The Cyxone Covid-19 clinical trial study results will be reported in Q3 2021.
”With this study concluded we focus all our resources on the ongoing start-up activities for the Rabeximod in RA trial and our preclinical activities for T20K.”
“I am very happy to report that we can conclude the Rabeximod in Covid-19 Phase 2 clinical study and initiate data analysis. We otherwise needed to make the decision to open sites in other regions where the Covid-19 pandemic is still raging. This would be possible but require more time and resources. Now we understand that expanding the trial is not needed. The readout from this study will yield important information that will guide development of Rabeximod for treatment of ARDS which Covid-19 and other viral infections of the lung establishes. Furthermore, we remain on track to report the study outcome by the end of Q3,” says Tara Heitner, CEO of Cyxone. ”With this study concluded we focus all our resources on the ongoing start-up activities for the Rabeximod in RA trial and our preclinical activities for T20K.”
Photo of Tara Heitner